

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/540,084-Conf. #7531
				Filing Date	April 7, 2006
				First Named Inventor	Mary Collins
				Art Unit	1644
				Examiner Name	I. I. Ouspenski
Sheet	1	of	3	Attorney Docket Number	M0274.70042US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US 2005/0180969	08/18/2005	Hardy et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		WO 04/0568754 A1	07/08/2004	Wyeth, et al.	T ⁶

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		ANASPEC Online Catalog (Catalog No. 54662), "Anti-PDCD1 (CT)." www.anaspec.com/pdfs/54662.pdf			
		ANSARI et al., 2003, "The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice," J. Exp. Med. 198: 63-69.			
		BENNETT et al., 2003, "Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL015 Responses," J. Immunol. 170: 711-718.			
		BLAZER et al., 2002, "PD-1 Engagement Provides and Inhibitory Signal Which Downregulates T Cell Alloresponses In Vivo," Blood 100: 72a, Abstract No. 261.			
		CARRENO et al., 2002, "The B7 Family of Ligands and Its Receptors: New Pathways for Costimulation and Inhibition of Immune Response," Annu. Rev. Immunol. 20: 29-53.			
		CURETECH Press Release, 2007, "CureTech announces receipt of a Notice of Allowance from the US Patent and Trademark Office"			
		CURETECH , http://www.curetechbio.com/?TemplateID=29&PageID=145&TemplateType=14			
		DAVIES et al., 1996, "Affinity Improvement of Single Antibody VH Domains: Residues in All Three Hypervariable Regions Affect Antigen Binding," Immunotechnology 2: 169-179.			
		DE KRUIF et al., 1995, "Selection and Application of Human Single Chain Fv Antibody Fragments from a Semi-synthetic Phage Antibody Display Library with Designed CDR3 Regions," J. Mol. Biol. 248, pp. 97-105.			
		DESMYTER A. et al., 2001, "Antigen Specificity and High Affinity Binding Provided by One Single Loop of a Camel Single-Domain Antibody", The Journal of Biological Chemistry, Vol.			

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications). -

1210262.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/540,084-Conf. #7531
				Filing Date	April 7, 2006
				First Named Inventor	Mary Collins
				Art Unit	1644
				Examiner Name	I. I. Ouspenski
Sheet	2	of	3	Attorney Docket Number	M0274.70042US02

	276, No. 28, pp. 26285-26290.	
	HOLLING, T. et al., 2004, "Function and Regulation of MHC Class II Molecules in T-Lymphocytes: Of Mice and Men," Human Immunology 65: 282-290.	
	ISHIDA Y. et al., 1992, "Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death," EMBO Journal, 11:11, pp. 3887-3895	
	JIRHOLT. P. et al., 1998, "Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework," Gene, 215, pp 471-476.	
	LADNER et al., 2007, "Antibodies cut down to size," Nat Biotechnol, Aug;25(8):875-7.	
	LEVI et al., 1993, "A Complementarity-Determining Region Synthetic Peptide Acts as a Miniantibody and Neutralizes Human Immunodeficiency Virus Type 1 In Vitro," Proc. Natl. Acad. Sci., 90: 4374-4378.	
	MARKS, J. D. et al., 1992, "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," Bio/Technology, Vol. 10, pp. 779783.	
	MAYNARD J. and GEORGIOU G., 2000, "Antibody Engineering," Annu. Rev. Biomed. Eng, 02 pp. 339-76.	
	NISHIMURA, H. et al., 1999, "Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor," Immunity. Vol. 11, pp. 141-151.	
	QIU et al., 2007, "Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting," Nat Biotechnol. 2007 Aug;25(8):921-9. Epub.	
	REITER, Y et al., 1999, "An Antibody Single-domain Phage Display Library of a Native Heavy Chain Variable Region: Isolation of Functional Single-domain VH Molecules with a Unique Interface," J. Mol. Biol. 290, pp. 685-698.	
	SÖDERLIND, E. et al., 2000, "Recombinant germline-derived CDR sequences for creating diverse single-framework antibody libraries," Nature Biotechnology, Vol 18, pp. 852-856.	
	SÖDERLIND, E. et al., 1999, "Complementarity-determining region (CDR) implantation: a theme of recombination," Immunotechnology, 4, pp. 279-285.	
	WARD et al., 1989, "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from Escherichia Coli," Nature 341: 544-546	
	WELLING, et al., 1991, "A Ten-Residue Fragment of an Antibody (Mini-Antibody) Directed Against Lysozyme as Ligand in Immunoaffinity Chromatography," J. Chromatography, 548: 235-242.	
	WILLIAMS et al., 1989, "Development of Biologically Active Peptides Based on Antibody Structure," Proc. Natl. Acad. Sci. 86: 5537-5541.	
	XU J. L. and DAVIS M. M., "Diversity in the CDR3 Region of V _H is Sufficient for Most Antibody Specificities," Immunity, Vol 13, pp. 37-45.	
	ZHONG, X. et al., 2004, "Suppression of expression and function of negative immune	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications). -

1210262.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/540,084-Conf. #7531
				Filing Date	April 7, 2006
				First Named Inventor	Mary Collins
				Art Unit	1644
				Examiner Name	I. I. Ouspenski
Sheet	3	of	3	Attorney Docket Number	M0274.70042US02

		regulator PD-1 by certain pattern recognition and cytokine receptor signals associated with immune system danger," Int'l Immunology, 16:8, pp. 1181-1188.	
		Accession No. Q15116 (2003)	
		Accession No. NM_008798 (2003)	

EXAMINER: /Ilia Ouspenski/	DATE CONSIDERED: 06/05/2008
-----------------------------------	------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications). -

1210262.1 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./